Oxytocin Conditional Knockout Mouse Model for Studying Behavioral Effects
Treatment of Alcoholism by Inhibition of the Neuropeptide Y Receptor
SIRT2 Inhibitors as Novel Therapeutics for Myocardial Infarction and Ischemic Stroke and to Prevent Necrosis
Generation of Artificial Mutation Controls for Diagnostic Testing
Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis
Method to Detect and Quantify In Vivo Mitophagy
This technology includes a transgenic reporter mouse that expresses a fluorescent protein called mt-Keima, to be used to detect and quantify in vivo mitophagy. This fluorescent protein was originally described by a group in Japan and shown to be able to measure both the general process of autophagy and mitophagy. We extended these results by creating a living animal so that we could get a measurement for in vivo mitophagy. Our results demonstrate that our mt-Keima mouse allows for a straightforward and practical way to quantify mitophagy in vivo.
Methods To Regulate Metabolism For Treatment Of Neural Injuries and Neurodegeneration
Axonal injury and subsequent neuronal death underpin the pathology of many neurological disorders from acute neural injuries (motor vehicle crashes, combat related injuries, traumatic brain injuries) to neurological diseases (multiple sclerosis, glaucoma). In the central nervous system (CNS), microglia help respond to CNS injuries by mediating the immune response and increasing inflammation at the site of injury.
Establishment of Induced Pluripotent Stem Cells (iPSC) from the Thirteen-lined Ground Squirrel
The limited choice in cell types available for in vitro studies has become an obstacle in hibernation research.
Researchers at the National Eye Institute for the first time have successfully established iPSC line(s) from a mammalian hibernator, which can be potentially used to generate various cell types and tissue models for in-depth mechanistic studies of hibernation and coldness tolerance in vitro.
Glial Cell Line-Derived Neurotrophic Factor for the Treatment of Neurodegenerative Diseases and Diabetes
The National Institute on Drug Abuse (NIDA) is seeking interested parties to license or co-develop GDNFOS peptides and non-coding RNAs as therapeutic agents for neurodegenerative diseases.